AEZS Aeterna Zentaris Inc.

-0.05  -2%
Previous Close 2.15
Open 2.19
Price To Book -11.67
Market Cap 34,921,509
Shares 16,440,760
Volume 66,012
Short Ratio
Av. Daily Volume 112,396

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Phase 3 trial did not meet primary endpoint - May 1, 2017.
Endometrial cancer

Latest News

  1. Aeterna Zentaris (AEZS) Beats Q2 Earnings Estimates
  2. Aeterna Zentaris Reports Second Quarter 2019 Financial and Operating Results
  3. Will Aeterna Zentaris (AEZS) Report Negative Q2 Earnings? What You Should Know
  4. Options Traders Expect Huge Moves in Aeterna Zentaris (AEZS) Stock
  5. Aeterna Zentaris Provides Corporate Update
  6. Aeterna Zentaris Announces Results of Annual and Special Shareholders’ Meeting
  7. Aeterna Zentaris (AEZS) Reports Q1 Loss, Misses Revenue Estimates
  8. Aeterna Zentaris: 1Q Earnings Snapshot
  9. Aeterna Zentaris Reports First Quarter 2019 Financial and Operating Results
  10. What's in the Cards for AEterna (AEZS) This Earnings Season?
  11. Analysts Estimate Aeterna Zentaris (AEZS) to Report a Decline in Earnings: What to Look Out for
  12. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2018 Financial and Operating Results
  13. Aeterna Zentaris to Announce Fourth Quarter and Year End 2018 Financial and Operating Results on March 26, 2019
  14. Aeterna Zentaris (AEZS) Moves to Buy: Rationale Behind the Upgrade
  15. The Daily Biotech Pulse: AEterna Zentaris Explores Options, Verastem Plunges On Weak Copiktra Sales, FDA Nod For Aerie
  16. Aeterna Zentaris Announces Strategic Review and Engagement of Financial Advisor
  17. What's in the Cards for Aeterna (AEZS) This Earnings Season?
  18. The Zacks Analyst Blog Highlights: Celgene, Charles River Laboratories International, Catalent and Aeterna Zentaris
  19. 4 Drug Stocks to Buy Despite Price Hearing Woes